Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
Lists
Only you see this
Abstract
Even in a contemporary era with prevalent osimertinib use, the baseline and longitudinal risk of BM development was high. The ongoing risk of developing BM, together with the associated survival detriment, argues for routine surveillance of the brain through magnetic resonance imaging for patients with EGFRm NSCLC, which is not currently included in the guidelines.
BibTeX
@inproceedings{stalker2024changing,
author = {Margaret Stalker and Connor B. Grady and Alan G. Watts and Wei‐Ting Hwang and Krishna Chandrasekhara and Fangdi Sun and Geoffrey Liu and Devalben Patel and Jorge J. Nieva and Amanda Herrmann and Kristen A. Marrone and Vincent K. Lam and Vamsidhar Velcheti and Stephen V. Liu and Gabriela Liliana Bravo Montenegro and William Tompkins and Tejas Patil and Jared Weiss and Kelsey Leigh Miller and William Schwartzman and Jonathan E. Dowell and Khvaramze Shaverdashvili and Liza C. Villaruz and Amanda Cass and Wade T. Iams and Dara L. Aisner and Charu Aggarwal and D. Ross Camidge and Lova Sun and Melina E. Marmarelis},
title = {{Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis}},
booktitle = {JTO},
year = {2024},
doi = {10.1016/j.jtocrr.2024.100765},
}Loading related content...